BGLC VS BPTH Stock Comparison

Performance

BGLC
10/100

BGLC returned -97.12% in the last 12 months. Based on SPY's performance of -13.73%, its performance is below average giving it a score of 10 of 100.

BPTH
10/100

BPTH returned -67.39% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

BGLC
33/100

Out of the last 18 quarters, BGLC has had 6 profitable quarters and has increased their profits year over year on 4 of them.

BPTH
10/100

Out of the last 20 quarters, BPTH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BGLC
56/100

BGLC has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

BPTH
42/100

BPTH has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

Analyst Price Targets

BGLC

"Analyst Price Targets" not found for BGLC

BPTH
75/100

2 analysts offer 12-month price targets for BPTH. Together, they have an average target of 0, the most optimistic target put BPTH at 0 within 12-months and the most pessimistic has BPTH at 0.

Technicals

BGLC

"Technicals" not found for BGLC

BPTH
14/100

BPTH receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

BGLC

"Earnings" not found for BGLC

BPTH
10/100

BPTH has missed earnings 10 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

BioNexus Gene Lab Corp Common stock Summary

Nasdaq / BGLC

Healthcare

Medical - Diagnostics & Research

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Bio-Path Holdings Inc Summary

Nasdaq / BPTH

Healthcare

Biotechnology

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Power up your portfolio